VCNX (Vaccinex) ROCE %: 0.00% (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VCNX Vaccinex Inc VCNX
50 GF Score
Price $1.18
View Full Analysis

What is Vaccinex ROCE %?

Vaccinex VCNX 50 ROCE % is 0.00% as of Dec. 2024. GuruFocus rates VCNX with a GF Score™ of 50/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vaccinex's annualized ROCE % for the quarter that ended in Dec. 2024 was 0.00%.

Vaccinex  (OTCPK:VCNX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vaccinex ROCE % Related Terms

Vaccinex ROCE % Historical Data

* Premium members only.

The historical data trend for Vaccinex's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaccinex ROCE % Chart

Vaccinex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only 0.00 -706.20 -304.18 -1,283.68 0.00

Vaccinex Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -8,231.91 0.00 0.00 0.00
VCNX
50GF Score
Vaccinex Inc VCNX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaccinex ROCE % Calculation

Vaccinex's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-18.632/( ( (3.631 - 5.916) + (2.596 - 5.084) )/ 2 )
=-18.632/( (-2.285+-2.488)/ 2 )
=-18.632/-2.3865
=780.72 %

Vaccinex's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=-13.488/( ( (4.854 - 6.175) + (2.596 - 5.084) )/ 2 )
=-13.488/( ( -1.321 + -2.488 )/ 2 )
=-13.488/-1.9045
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Vaccinex (VCNX) has a ROCE % of 0.00% as of Dec. 2024.
Is Vaccinex's ROCE % too high?
Vaccinex's current ROCE % is 0.00%. Overall, Vaccinex has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Vaccinex's ROCE % compare to SXTP and PHGE?
Vaccinex's ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Vaccinex's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaccinex stock overvalued right now?
Vaccinex (VCNX) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Vaccinex's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vaccinex (VCNX), the current ROCE % is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaccinex Business Description

Address 1895 Mount Hope Avenue, Rochester, NY, USA, 14620
Vaccinex Inc is a clinical stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company operates and manages its business as one operating and reportable segment, which is the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. The firm has also developed a proprietary drug discovery platform, ActivMAb.
50GF Score

Get the complete analysis for VCNX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price